Combinations of Taxanes and Ionizing Radiation

  • Luka Milas
  • Kathryn A. Mason
  • Zhongxing Liao
  • Kian K. Ang
Part of the Medical Radiology book series (MEDRAD)


Enhancement Factor Radiat Oncol Biol Phys Mitotic Arrest Tumor Growth Delay Human Ovarian Cancer Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bhalla K, Ilerado AM, Tourkina E et al (1993) Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 7:563–568PubMedGoogle Scholar
  2. Bissery MC, Vrignaud P, Lavelle F (1995) Preclinical profile of docetaxel (Taxotere): efficacy as a single agent and in combination. Semin Oncol 22(Suppl 13):3–16Google Scholar
  3. Blagosklonny MV, Schulte T, Nguyen P et al (1996) Taxol-induced apoptosis and phosphorylation of bcl-2 protein involves c-Raf-1 signal transduction pathway. Cancer Res 56:1851–1854PubMedGoogle Scholar
  4. Bogden D, Ding AH (1992) Taxol, a microtubule stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages. J Leukoc Biol 52:119–121Google Scholar
  5. Brizel DM, Albers ME, Fisher SR et al (1998) Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798–804PubMedCrossRefGoogle Scholar
  6. Burkhart CA, Berman JW, Swindell CS et al (1994). Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-alpha gene expression and cytotoxicity. Cancer Res 54:5779–5782PubMedGoogle Scholar
  7. Chen Y, Okunieff P (2004) Radiation and third-generation chemotherapy. Hematol Oncol Clin N Am 18:55–80CrossRefGoogle Scholar
  8. Choy H (2000) Taxanes in combined modality therapy for solid tumors. Crit Rev Oncol Hematol 37:237–247Google Scholar
  9. Choy H, Rodriguez FF, Koester S et al (1993) Investigation of taxol as a potential radiation sensitizer. Cancer 71:3774–3778PubMedCrossRefGoogle Scholar
  10. Choy H, Akerley W, Safran H et al (1994) Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 12:2682–2686PubMedGoogle Scholar
  11. Debernardis D, Graniela-Sire E, De Feudis P et al (1997) p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 57:870–874PubMedGoogle Scholar
  12. Figgitt DP, Wiseman LR (2000) Docetaxel an update of its use in advance breast cancer. Drugs 59:621–651PubMedCrossRefGoogle Scholar
  13. Furuse K, Fukuoka M, Kawahara M et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17: 2692–2699PubMedGoogle Scholar
  14. Gangemi RMR, Tiso M, Marchetti C et al (1995) Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death. Cancer Chemother Pharmacol 36:385–392PubMedGoogle Scholar
  15. Geard CR, Jones JM (1994) Radiation and taxol effects on synchronized human cervical carcinoma cells. Int J Radiat Oncol Biol Phys 29:565–569PubMedGoogle Scholar
  16. Gigorov J, Lotz JP (2004) Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9:3–8CrossRefGoogle Scholar
  17. Gorski DH, Beckett MA, Jaskowiak NT et al (1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374–3378PubMedGoogle Scholar
  18. Graniela-Sire EA, Vikhanskaya F, Broggini M (1995) Sensitivity and cellular response to different anticancer agents of a human ovarian cancer cell line expressing wild-type, mutated or no p53. Ann Oncol 6:589–593PubMedGoogle Scholar
  19. Griffon-Etienne G, Merlin JL, Marchal C (1996) In vitro evaluation of taxol combined with radiation in human squamous cell carcinoma spheroids. Cancer Lett 109:23–32PubMedCrossRefGoogle Scholar
  20. Griffon-Etienne G, Boucher Y, Brekken C et al (1999) Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 59:3776–3782PubMedGoogle Scholar
  21. Grunberg E, Eckert K, Maurer HR (1998) Docetaxel treatment of HT-29 colon carcinoma cells reinforces the adhesion and immunocytotoxicity of peripheral blood lymphocytes in vitro. Int J Oncol 12:957–963PubMedGoogle Scholar
  22. Gueritte-Voegelein F, Guenard D, Lavelle F et al (1991) Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 34:992–998PubMedCrossRefGoogle Scholar
  23. Gupta N, Hu LJ, Deen DF (1997) Cytotoxicity and cell-cycle effects of paclitaxel when used as a single agent and in combination with ionizing radiation. Int J Radiat Oncol Biol Phys 37:885–895PubMedCrossRefGoogle Scholar
  24. Haimovitz-Friedman A, Vlodavsky I, Chaudhur A et al (1991) Autocrine effects of fibroblast growth factor in repair of radiation damage in endothelial cells. Cancer Res 51:2552–2558PubMedGoogle Scholar
  25. Haldar S, Chintapalli J, Croce CM (1996) Taxol-induced bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56:1253–1255PubMedGoogle Scholar
  26. Haldar, S, Basu A, Croce CM (1997) Bcl-2 is the guardian of microtubule integrity. Cancer Res 57:229–233PubMedGoogle Scholar
  27. Hanauske AR, Degen D, Hilsenbeck SG et al (1992) Effects of taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 3:121–124PubMedCrossRefGoogle Scholar
  28. Hennequin N, Giocanti N, Favaudon V (1995) S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer 71:1194–1198PubMedGoogle Scholar
  29. Hennequin C, Giocanti N, Favaudon V (1996) Interaction of ionizing radiation with paclitaxel (taxol) and docetaxel (taxotere) in HeLa and SQ20B cells. Cancer Res 56:1842–1850PubMedGoogle Scholar
  30. Herskovic A, Martz K, Al-Sarraf M et al (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326:1593–1598PubMedCrossRefGoogle Scholar
  31. Horwitz SB (2004) Personal recollections of the early development of taxol. J Nat Prod 67:136–138PubMedCrossRefGoogle Scholar
  32. Ingram ML, Redpath JL (1997) Subadditive interaction of radiation and taxol in vitro. Int J Radiat Oncol Biol Phys 37:1139–1144PubMedCrossRefGoogle Scholar
  33. Jaakkola M, Rantanen V, Grenman S et al (1996) In vitro concurrent paclitaxel and radiation of four vulvar squamous cell carcinoma cell lines. Cancer 77:1940–1946PubMedCrossRefGoogle Scholar
  34. Joschko MA, Webster LK, Groves J et al (1994) Taxol enhances radiation effect in a hypopharyngeal xenograft. Forty-Second Annual Meeting of the Radiation Research Society Book of Abstracts p. 206, (Abstr no. P24–400)Google Scholar
  35. Kastan MB, Canman CE, Leonard CJ (1995) P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 14:3–15PubMedCrossRefGoogle Scholar
  36. Kelland LR, Abel G (1992) Comparative in vitro cytotoxicity of taxol and taxotere against cisplatin-sensitive and-resistant human ovarian cancer cell lines. Cancer Chemother Pharmacol 30:444–450PubMedCrossRefGoogle Scholar
  37. Lavelle F, Bissery MC, Combeau C et al (1995) Preclinical evaluation of docetaxel (taxotere). Semin Oncol 22(Suppl 4):3–16Google Scholar
  38. Lee L-F, Li G, Templeton DJ et al (1998) Paclitaxel (taxol)-induced gene expression and cell death are both mediated by activation of c-Jun NH2-terminal kinase (JNK/SAPK). J. Biol Chem 273:28253–28260PubMedCrossRefGoogle Scholar
  39. Leonard CE, Chan DC, Chou TC et al (1996) Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res 56:5198–5204PubMedGoogle Scholar
  40. Li C, Price JE, Milas L et al (1999) Antitumor activity of Poly (L-glutamic acid)-Paclitaxel on syngeneic and xenografted tumors. Clin Cancer Res 5:891–897PubMedGoogle Scholar
  41. Li C, Ke S, Wu QP et al (2000a) Potentiation of ovarian OCa-1 tumor radioresponse by poly (L-glutamic acid)-paclitaxel conjugate. Int J Radiat Oncol Biol Phys 48:1119–1126PubMedCrossRefGoogle Scholar
  42. Li C, Ke S, Wu QP et al (2000b) Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy. Clin Cancer Res 6:2829–2834PubMedGoogle Scholar
  43. Liebmann J, Cook JA, Fisher J et al (1994a) Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (Taxol). Int J Radiat Oncol Biol Phys 29:559–564PubMedGoogle Scholar
  44. Liebmann J, Cook JA, Fisher J et al (1994b) In vitro studies of taxol as a potential radiation sensitizer. J Natl Cancer Inst 86:441–446PubMedGoogle Scholar
  45. Liebmann J, Herscher L, Fisher J et al (1996) Antagonism of paclitaxel cytotoxicity by X-rays: implications for the sequence of combined modality therapy. Int J Oncol 8:991–996Google Scholar
  46. Lokeshwar BL, Farrell SM, Block NL (1995) Enhancement of radiation response of prostatic carcinoma by taxol: therapeutic potential for late-stage malignancy. Anticancer Res 15:93–98PubMedGoogle Scholar
  47. Lowe SW, Ruley HE, Jacks T et al (1993) p-53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957–967PubMedCrossRefGoogle Scholar
  48. Mangatal L, Adeline MT, Guenard D et al (1989) Application of the vicinal hydroxyamination reaction with asymmetric induction to the hemisynthesis of taxol and analogs. Tetrahedron 45:4177–4190CrossRefGoogle Scholar
  49. Manthey CL, Perera PY, Salkowski CA et al (1994) Taxol provides a second signal for murine macrophage tumoricidal activity. J Immunol 152:825–831PubMedGoogle Scholar
  50. Mason KA, Milas L, Peters LJ (1995) Effect of paclitaxel (Taxol) alone and in combination with radiation on the gastrointestinal mucosa. Int J Radiat Oncol Biol Phys 32:1381–1389PubMedCrossRefGoogle Scholar
  51. Mason KA, Hunter NR, Milas M et al (1997) Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 3:2431–2438PubMedGoogle Scholar
  52. Mason KA, Kishi K, Hunter N et al (1999) Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res 54:4191–4198Google Scholar
  53. Mason K, Staab A, Hunter N et al (2001a) Enhancement of tumor radioresponse by docetaxel: involvement of immune system. Int J Oncol 18:599–606PubMedGoogle Scholar
  54. Mason KA, Komaki R, Cox JD et al (2001b) Biology-based combined-modality radiotherapy: workshop report. Int J Radiat Oncol Biol Phys 50:1079–1089PubMedCrossRefGoogle Scholar
  55. Mason KA, Wiedenmann N, Valdecanas D et al (in press) ABI-007, nanoparticle albumin-bound paclitaxel, enhances tumor radioresponse. Proc American Association of Cancer Research meeting, Abstract no. 06-AB-3086Google Scholar
  56. Milas L, Hunter NR, Mason KA et al (1994) Enhancement of tumor radioresponse of a murine mammary carcinoma by taxol. Cancer Res 54:3506–3510PubMedGoogle Scholar
  57. Milas L, Hunter NR, Kurdoglu B et al (1995a) Kinetics of mitotic arrest and apoptosis in murine mammary ovarian tumors treated with taxol. Cancer Chemother Pharmacol 35:297–303PubMedGoogle Scholar
  58. Milas L, Hunter NR, Mason KA et al (1995b) Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 55:3564–3568PubMedGoogle Scholar
  59. Milas L, Saito Y, Hunter NR et al (1996) Therapeutic potential of paclitaxel radiation treatment of a murine ovarian carcinoma. Radiother Oncol 40:163–170PubMedCrossRefGoogle Scholar
  60. Milas L, Milas M, Mason KA (1999) Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol 9:12–26PubMedGoogle Scholar
  61. Milas L, Mason KA, Hunter N et al (2003a) Poly (L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability. Int J Radiat Oncol Biol Phys 55:707–712PubMedCrossRefGoogle Scholar
  62. Milas L, Mason KA, Liao Z et al (2003b) Chemoradiotherapy: emerging treatment improvement strategies. Head Neck 25:152–167PubMedCrossRefGoogle Scholar
  63. Milross CG, Mason KA, Hunter NR et al (1996) Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 88:1308–1314PubMedGoogle Scholar
  64. Milross CG, Mason KA, Hunter NR et al (1997) Enhanced radioresponse of paclitaxel-sensitive and-resistant tumors in vivo. Eur J Cancer 33:1299–1308PubMedCrossRefGoogle Scholar
  65. Minarik L, Hall EJ (1994) Taxol in combination with acute and low dose rate irradiation. Radiother Oncol 32:124–128PubMedCrossRefGoogle Scholar
  66. Morris M, Eifel PJ, Lu J et al (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic radiation for high-risk cervical cancer. N Engl J Med 340:1137–1143PubMedCrossRefGoogle Scholar
  67. Morse DL, Gray H, Payne CM et al (2005) Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther 4:1495–1504PubMedCrossRefGoogle Scholar
  68. Piccart MJ, Gore M, Huinink WTB et al (1995) Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87:676–681PubMedGoogle Scholar
  69. Ringel I, Horwitz SB (1991) Studies with RP 56976 (Taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83:288–291PubMedGoogle Scholar
  70. Rodriguez M, Sevin BU, Perras J et al (1995) Paclitaxel: a radiation sensitizer of human cervical cancer cells. Gynecol Oncol 57:165–169PubMedCrossRefGoogle Scholar
  71. Rosell R, Gonzalez-Larriba JL, Alberola V et al (1995) Single-agent paclitaxel by 3-hour infusion in the treatment of nonsmall cell lung cancer: links between p53 and K-ras gene status and chemosensitivity. Semin Oncol 22:12–18PubMedGoogle Scholar
  72. Rowinsky EK, Donehower RC (1995) Paclitaxel (Taxol). N Engl J Med 332:1004–1014PubMedCrossRefGoogle Scholar
  73. Schiff PB, Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77:1561–1565PubMedCrossRefGoogle Scholar
  74. Schiff PB, Fant S, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665–667PubMedCrossRefGoogle Scholar
  75. Schimming R, Mason KA, Hunter N et al (1999a) Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel. Cancer Chemother Pharmacol 43:165–172PubMedCrossRefGoogle Scholar
  76. Schimming R, Hunter NR, Mason KA et al (1999b) Apoptosis and inhibition of neoangiogenesis as mechanisms of antitumor action by docetaxel (Taxotere). Mund Kiefer Gesichts Chir 3:210–212CrossRefGoogle Scholar
  77. Shim J, Lee H, Park J et al (1996) A non-enzymatic p21 protein inhibitor of stress-activated protein kinases. Nature 381:804–806PubMedCrossRefGoogle Scholar
  78. Sinclair WK, Morton RA (1966) X-ray sensitivity during the cell generation cycle of cultured Chinese hamster ovary cells. Radiat Res 29:450–474PubMedGoogle Scholar
  79. Singer JW, Shaffer S, Baker B et al (2005) Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane. Anti Cancer Drugs 16:243–254PubMedCrossRefGoogle Scholar
  80. Sparreboom A, Scripture CD, Trieu V, et al (2005) Comparative preclinical and clinical pharmacokinetics of a cremophorfree, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol). Clin Cancer Res 11:4136–4143PubMedCrossRefGoogle Scholar
  81. Steren A, Sevin BU, Perras J et al (1993) Taxol sensitizes human ovarian cancer cells to radiation. Gynecol Oncol 48:252–258PubMedCrossRefGoogle Scholar
  82. Stromberg JS, Lee YJ, Armour EP et al (1995) Lack of radiosensitization after paclitaxel treatment of three human carcinoma cell lines. Cancer 75:2262–2268PubMedCrossRefGoogle Scholar
  83. Sweeney CJ, Miller KD, Sissons SE et al (2001) The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61:3369–3372PubMedGoogle Scholar
  84. Terasima T, Tolmach LJ (1963) Variations in several responses of HeLa cells to X-irradiation during the division cycle. Biophys J 3:11–33PubMedCrossRefGoogle Scholar
  85. Tishler RB, Geard CR, Hall EJ, Schiff PB (1992a) Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52:3495–3497PubMedGoogle Scholar
  86. Tishler RB, Schiff PB, Geard CR et al (1992b) Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22:613–617PubMedGoogle Scholar
  87. Tishler RB, Lampus DM, Park S et al (1995) Microtubuleactive drugs taxol, vinblastine, and nocodazole increase the level of transcriptionally active p53. Cancer Res 55:6021–6025PubMedGoogle Scholar
  88. Torres K, Horwitz SB (1998) Mechanisms of taxol-induced cell death are concentration dependent. Cancer Res 58:3620–3626PubMedGoogle Scholar
  89. Van Rijn J, Van Den Berg J, Meijer OW (1995) Proliferation and clonal survival of human lung cancer cells treated with fractionated irradiation in combination with paclitaxel. Int J Radiat Oncol Biol Phys 33:635–639PubMedCrossRefGoogle Scholar
  90. Wahl AF, Donaldson KL, Fairchild C et al (1996) Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nature Med 2:72–79PubMedCrossRefGoogle Scholar
  91. Wang T-H, Popp DM, Wang H-S et al (1999) Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and-independent pathways in ovarian cancer cells. J Biol Chem 274:8208–8216PubMedCrossRefGoogle Scholar
  92. Wani MC, Taylor HL, Wall ME et al (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325–2327PubMedCrossRefGoogle Scholar
  93. Withers HR, Elkind MM (1970) Microcolony survival assay for cells of mouse intestinal mucosa exposed to radiation. Int J Radiat Biol 17:261–267Google Scholar
  94. Woods CM, Zhu J, Mcqueney PA et al (1995) Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1:506–526PubMedGoogle Scholar
  95. Xia Z, Dickens M, Raingeaud J et al (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Scinece 270:1326–1331Google Scholar
  96. Zanelli GD, Quaia M, Robieux I et al (1997) Paclitaxel as a radiosenitizer: a proposed schedule of administration based on in vitro data and pharmacokinetic calculations. Eur J Cancer 33:486–492PubMedCrossRefGoogle Scholar
  97. Zhao J, Kim JE, Reed E et al (2005) Molecular mechanism of antitumor activity of taxanes in lung cancer (Review). Int J Oncol 27:247–256PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • Luka Milas
    • 1
  • Kathryn A. Mason
    • 1
  • Zhongxing Liao
    • 1
  • Kian K. Ang
    • 2
  1. 1.Department of Experimental Radiation OncologyUniversity of Texas M.D. Anderson Cancer CenterHoustonUSA
  2. 2.Departments of Experimental Radiation Oncology and Radiation OncologyUniversity of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations